RARE raises PT to $58 on US accelerated approval of GENFLYCOS
RARE’s price target is raised to $58 from $45 following US accelerated approval of GENFLYCOS ahead of PDUFA, per Hammerstone MarketTalk at Citi.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.